Intellia Therapeutics (NTLA) AGM 2024 summary

Opening remarks and agenda

• Chairperson welcomed attendees and introduced the board and executive team, including key officers and Deloitte & Touche LLP as the independent auditor.

• The meeting agenda was set to follow the 2024 Notice of Annual Meeting and Proxy Statement.

Board and executive committee updates

• Board members and executive officers present were introduced, including roles such as CEO, CFO, CTO, CMO, and others.

• Inspector of Elections and Secretary roles were assigned, with the Inspector taking an oath of impartiality.

Shareholder proposals

• Four proposals were presented: election of two Class II directors, ratification of Deloitte & Touche LLP as auditor, advisory approval of executive compensation, and amendment to limit certain officer liabilities.